Suchergebnisse - Dominik Heinzmann

  • Treffer 1 - 5 von 5
Treffer weiter einschränken
  1. 1
    Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III Hannah Study

    Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III Hannah Study von Roberto Hegg, Tadeusz Pieńkowski, S. Chen, Elżbieta Starosławska, S. Falcon, Н. В. Коваленко, N. Al-Sakaff, Dominik Heinzmann, Gerry Kolaitis, Gustavo Ismael

    Veröffentlicht 2012
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  2. 2
    Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer

    Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive... von Angelica Quartino, Carina Hillenbach, Jing Li, Hanbin Li, Russell Wada, Jennifer Visich, Chunze Li, Dominik Heinzmann, Jin Y. Jin, Bert L. Lum

    Veröffentlicht 2015
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  3. 3
    Additional Safety Results of Hannah: A Phase III Randomised, Open-Label, International Study of the Subcutaneous Formulation of Trastuzumab (H) in HER2-Positive Early Breast Cancer Patients

    Additional Safety Results of Hannah: A Phase III Randomised, Open-Label, International Study of the Subcutaneous Formulation of Trastuzumab (H) in HER2-Positive Early Breast Cancer... von Christian Jackisch, Magdolna Dank, G. Frasci, K.H. Park, R.I. Lopez, Marilyn F.M. Johnston, Dominik Heinzmann, H. Wéber, Gustavo Ismael

    Veröffentlicht 2012
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

    Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer von Christian Jackisch, Daniil Stroyakovskiy, Xavier Pivot, Jin Seok Ahn, Bohuslav Melichar, Shin‐Cheh Chen, Christoph Meyenberg, N. Al-Sakaff, Dominik Heinzmann, Roberto Hegg

    Veröffentlicht 2019
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  5. 5
    HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up

    HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuva... von Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, Jin‐Seok Ahn, Bohuslav Melichar, Shin‐Cheh Chen, Sung‐Bae Kim, Mikhail Lichinitser, Elżbieta Starosławska, G. Kunz, S. Falcon, Shou‐Tung Chen, A. Crepelle-Fléchais, Dominik Heinzmann, Mona Shing, Xavier Pivot

    Veröffentlicht 2016
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: